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BMC Medicine was launched in November 2003 as an open access, open peer-reviewed general medical journal
that has a broad remit to publish “outstanding and influential research in all areas of clinical practice, translational
medicine, medical and health advances, public health, global health, policy, and general topics of interest to the
biomedical and sociomedical professional communities”. Here, I discuss the last 15 years of epidemiological research
published by BMC Medicine, with a specific focus on how this reflects changes occurring in the field of epidemiology
over this period; the impact of ‘Big Data’; the reinvigoration of debates about causality; and, as we increasingly work
across and with many diverse disciplines, the use of the name ‘population health science’. Reviewing all publications
from the first volume to the end of 2018, I show that most BMC Medicine papers are epidemiological in nature, and the
majority of them are applied epidemiology, with few methodological papers. Good research must address important
translational questions that should not be driven by the increasing availability of data, but should take appropriate
advantage of it. Over the next 15 years it would be good to see more publications that integrate results from several
different methods, each with different sources of bias, in a triangulation framework.
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Background
In the 15 years since BMC Medicine was launched in
November 2003, epidemiology has led the challenge
of ‘Big Data’ science [1], reinvigorated debates about
what can legitimately be considered causes of diseases
and what methods should be used to determine caus-
ality (e.g., [2, 3]), and become increasingly known as
‘population health science’ [4]. These three changes
are related to each other and to broader changes in
science and society, as well as being rooted in a much
longer history going back decades if not centuries. I
thought it would be interesting to consider how these
recent changes are reflected in the last 15 years of
BMC Medicine. To do this, I undertook a review of
the types of studies published by BMC Medicine in
the last 15 years (see Fig. 1 and Additional file 1 for
the methodology used to prepare this figure). I was
pleased to see that most of the published research ar-
ticles were epidemiology studies (Fig. 1a; 981/1334;
74%). Most of the epidemiology papers were applied
studies (Fig. 1a; 946/981; 96%). This is a common
finding in general medical journals, despite the exist-
ence of several specific epidemiology journals [5]. The
few papers that I considered to be methodological
(Fig. 1b; 35/981; 4%) were largely concerned with
methods for developing or refining tools to measure
risk factors or disease outcomes (e.g., [6, 7]), rather
than research into analytical or study design methods.
There was little evidence that authors were using di-
rected acyclic graphs (DAGs) to demonstrate statis-
tical assumptions [8].
Big data
‘Big Data’ has no clear definition, but the term can be
used to refer to datasets with many participants and/
or many variables. The former category includes
large-scale record linkage studies; the latter includes
the integration of multiple ‘omics data with socioeco-
nomic, environmental, lifestyle and clinical data in
epidemiological studies and the collection of intense,
continuously measured data, such as glucose levels
collected by sensors at short, regular intervals. The
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current BMC Medicine call for papers in this area
notes: “Big Data in Medicine can be used to provide
health profiles and predictive models around individ-
ual patients. The use of high-throughput data to inte-
grate genetic and clinical inter-relationships; real-
world data to infer biological principles as well as as-
sociations, trajectories and stratifications of patients;
data-driven approaches for patients and digital plat-
forms are the hope for medical problems and evi-
dence-based medicine” [9].
However, as Saracci has eloquently highlighted, ex-
cessive claims for ‘Big Data’, such as is proposed in
this statement, can result in ‘bigness’ overriding the
key principles of epidemiology and good science.
These principles include, for example, the need for
data (and software) validity, replication or validation
of results in independent studies and, importantly,
using data to address the most relevant questions ra-
ther than ‘blind [big] data dredging’ [1]. As with other
journals, BMC Medicine has published a small pro-
portion of ‘omics studies (Fig. 1b; 77/981 (8%) of the
epidemiology papers included some ‘omics measure-
ments) and most of these were small and had no in-
dependent replication or validation (e.g., [10–12]).
Larger studies that did include replication (e.g., [13,
14]) have been published more recently.
A
B
Fig. 1 Research articles and ‘epidemiology’ research articles published in BMC Medicine, 2003–2018. a the proportion of all research articles that
were epidemiology studies, by years. b the proportion of epidemiology study papers that were methodological or included any ‘omics measurements
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Population health science
The increasing use of the term ‘population health sci-
ence’ in part reflects the potential for epidemiologists to
undertake population level physiology and embed this
in what was previously called ‘social medicine’. This is
enabled by the integration of multiple ‘omics data with
socioeconomic, lifestyle and clinical data in large cohort
studies. Multidisciplinary (i.e., people or groups from
different disciplines working together on research pro-
jects by drawing on their specific disciplinary know-
ledge) and interdisciplinary (i.e., synthesising methods
and knowledge from different disciplines to answer re-
search questions) approaches are needed to realise the
full potential of these data [4]. Thus, over the last 15
years, epidemiologists have increasingly learnt the
theories and language of colleagues from diverse funda-
mental and emerging disciplines, including mathemat-
ics, biology, chemistry, data and computer science and
(bio)informatics [15–17]. We have worked in large col-
laborations with these disciplines, as well as with social
and clinical scientists, with whom we have a long
tradition of working. This multidisciplinary and inter-
disciplinary work with population data has been called
‘population health science’ [4].
Causality, Mendelian randomisation and triangulation
One of the most notable changes in epidemiology in
the last 15 years has been the increased use of Mendel-
ian randomisation (MR) [18]. MR is the use of genetic
data to explore causal effects of modifiable (non-gen-
etic) risk factors. The first formal proposal of this
method (as used over the last 15 years) was published
in February 2003 [18], just 9 months before the first
volume of BMC Medicine was published. Notably, in
that original paper – and particularly in a subsequent
paper – George Davey Smith acknowledges a long his-
tory of others who have suggested the use of genetic
variants in this way, including Fisher, who made the
link between randomised trials and the random segre-
gation of genetic variants in 1951 [19]. MR and other
new methods have stimulated debates about causality,
the underlying assumptions of different analytical
methods and the importance of acknowledging and ex-
ploring these [8]. This has resulted in epidemiologists
increasingly using DAGs to demonstrate their causal
analysis assumptions, particularly for new methods or
causal frameworks, such as MR. Over the last 15 years,
MR has been increasingly used to improve causal un-
derstanding of the effects of lifestyle risk factors and
pathophysiological targets on human health and disease
[20–24]. Alongside these applications, considerable ef-
forts have been made to develop methods to explore
the validity of the genetic instruments used in MR stud-
ies and the robustness of their results [25–34]. The
availability of summary results from large numbers of
genome-wide association studies (GWAS) that can be
used for two-sample MR [29], together with automated
tools (such as MR-Base [35]) for analysing these data
and performing sensitivity analyses, have contributed to
recent increases in the use of (two-sample) MR. This
shift is reflected in the results of my review of BMC
Medicine publications: just one MR study was pub-
lished before 2018. This paper, published in 2004, did
not use the term MR, but used MTHFR genetic variants
to explore the role of homocysteine in migraine [36].
By contrast, six MR studies were published in BMC
Medicine in 2018 [37–42], five of which used two-sam-
ple MR.
The ease with which two-sample MR can be under-
taken means that some authors can complete analyses in
minutes without giving sufficient thought to the import-
ance or relevance of the research question being ex-
plored. They may also fail to consider or discuss key
methodological issues (even when using automated sys-
tems developed specifically for two-sample MR). These
include whether the two samples are from the same
underlying population and whether the GWAS popula-
tion used is relevant for the research question. In
addition, replication of these two-sample MR findings
and triangulating them with results from other methods
with different underlying assumptions should be ex-
plored [29]. One notable example of the poor science
that can result from the rush to an ‘easy publication’ is
demonstrated by the comparison of results from two
studies published in 2016. Both studies applied two-
sample MR to the same publicly available data, but re-
ported diametrically opposing conclusions (one reported
that higher circulating C-reactive protein concentration
increased risk of schizophrenia, while the other con-
cluded that it decreased schizophrenia risk) [28]. Hart-
wig and colleagues demonstrated how one of the two
had not harmonised summary data across the two sam-
ples (Table 3 in [28]); that paper has subsequently been
retracted [43].
The use of triangulation is increasingly recognised
as key to exploring causal effects [44]. In this ap-
proach, results are compared from several different
epidemiological methods, each of which has different,
unrelated, key sources of bias. The idea is that if each
of these methods suggests that a risk factor is causally
related to an outcome, despite their different sources
of bias, confidence in the results increases and a true
causal effect is reflected. If results differ, by being ex-
plicit in the first instance about their different sources
of bias, it is possible to determine what further stud-
ies would be needed to obtain a robust causal answer
[44]. Going forwards, the potential for further extend-
ing this approach in a truly interdisciplinary way –
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including integrating data from (bio)informatics and
laboratory science – is an exciting possibility for the
next 15 or more years.
Data sharing and supporting team science
Changes in epidemiology over the last 15 years have co-
incided with debates about data-use and sharing [45]. In
cohort studies, there is no equivalent of the randomised
trial register that provides a means of exploring ‘data
dredging’ and publication bias. In a 2007 commentary, I
noted that with the increasing number of cohorts and
data within them that are, rightly, shared across the glo-
bal scientific community to investigate many different
hypotheses, it was nearly impossible to judge contribu-
tions to publication bias from observational epidemi-
ology [46]. I suggested then that this situation might be
improved by changing the journal publication process so
that authors submitted only the introduction and
methods of their study. In this way, decisions to publish
would not be dependent on the results (and whether or
not they reached some arbitrary P-value threshold). This
opinion had no influence on journal editors or re-
searchers and, in fact, my thoughts have changed since
then. I think accessing cohort data would benefit from
the requirement to submit a brief ‘protocol’ of planned
analyses that could serve as a ‘register’. These should be
kept as simple as possible and made public. They should
neither be used to judge (scientifically) whether data are
shared, nor to reject access on the basis of overlap with
other proposals. Two UK examples of this process are
the UK Biobank and the Avon Longitudinal Study of
Parents and Children (ALSPAC) [47, 48] (for transpar-
ency, I acknowledge that I have had a leading scientific
role in ALSPAC for the last 15 years). Debates about the
pros and cons of this approach versus access that does
not require registration are likely to continue, but I hope
over the coming years that more researchers, funders,
academic institutions and journal editors will insist on
clear policies for sharing of hypotheses, data and analysis
code between researchers. In addition, they should push
for ‘team science’, with recognition of all who contribute
(including those who recruit participants and collect and
process data).
Conclusions
As a new member of the BMC Medicine Editorial
Board, I am pleased to see that a consistently high pro-
portion of applied epidemiology papers have been pub-
lished over the last 15 years (Fig. 1a). As I read through
the titles and abstracts of each paper, I also sensed that
a high proportion of this research is from low and mid-
dle income countries, which I am also pleased about.
In the next 15 years, it would be nice to see the advice
to researchers from a recent Nature editorial reflected
in published BMC Medicine research: ‘In short, be
sceptical, pick a good question, and try to answer it in
many ways. It takes many numbers to get close to the
truth’ [49].
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